BRPI0919248A2 - derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol - Google Patents
derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazolInfo
- Publication number
- BRPI0919248A2 BRPI0919248A2 BRPI0919248A BRPI0919248A BRPI0919248A2 BR PI0919248 A2 BRPI0919248 A2 BR PI0919248A2 BR PI0919248 A BRPI0919248 A BR PI0919248A BR PI0919248 A BRPI0919248 A BR PI0919248A BR PI0919248 A2 BRPI0919248 A2 BR PI0919248A2
- Authority
- BR
- Brazil
- Prior art keywords
- aminoindazole
- amino
- tetrahydroindazole derivatives
- tetrahydroindazole
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08165137 | 2008-09-25 | ||
PCT/EP2009/061966 WO2010034657A1 (en) | 2008-09-25 | 2009-09-15 | 3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0919248A2 true BRPI0919248A2 (pt) | 2019-09-24 |
Family
ID=41382044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0919248A BRPI0919248A2 (pt) | 2008-09-25 | 2009-09-15 | derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol |
Country Status (14)
Country | Link |
---|---|
US (1) | US8153663B2 (pt) |
EP (1) | EP2346834B1 (pt) |
JP (1) | JP5450632B2 (pt) |
KR (1) | KR101444988B1 (pt) |
CN (1) | CN102164900B (pt) |
AR (1) | AR073396A1 (pt) |
AU (1) | AU2009295967A1 (pt) |
BR (1) | BRPI0919248A2 (pt) |
CA (1) | CA2736434A1 (pt) |
ES (1) | ES2443947T3 (pt) |
IL (1) | IL211674A0 (pt) |
MX (1) | MX2011002793A (pt) |
TW (1) | TW201020234A (pt) |
WO (1) | WO2010034657A1 (pt) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2344459B1 (en) * | 2008-09-25 | 2013-12-25 | F. Hoffmann-La Roche AG | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
US8252826B2 (en) * | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
JP5838497B2 (ja) * | 2010-05-25 | 2016-01-06 | シムライズ アーゲー | 抗セルライト有効成分としてのシクロヘキシルカルバメート化合物 |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
JP6366721B2 (ja) | 2013-09-11 | 2018-08-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | B型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
JP6678779B2 (ja) | 2016-06-13 | 2020-04-08 | ギリアード サイエンシーズ, インコーポレイテッド | Fxr(nr1h4)調節化合物 |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
ES2959842T3 (es) | 2017-02-21 | 2024-02-28 | Genfit | Combinación de un agonista de PPAR con un agonista de FXR |
CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
EP3600293A1 (en) | 2017-03-30 | 2020-02-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
KR20210114457A (ko) | 2019-01-15 | 2021-09-23 | 길리애드 사이언시즈, 인코포레이티드 | Fxr (nr1h4) 조정 화합물 |
US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
US20220241376A1 (en) | 2019-07-18 | 2022-08-04 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
MX2022008062A (es) | 2020-01-15 | 2022-07-27 | Inst Nat Sante Rech Med | Uso del agonista fxr para el tratamiento de una infeccion por el virus de la hepatitis d. |
KR20230154806A (ko) | 2021-01-14 | 2023-11-09 | 엔요 파마 | Hbv 감염 치료를 위한 fxr 작용제 및 ifn의 상승작용효과 |
EP4329761A1 (en) | 2021-04-28 | 2024-03-06 | ENYO Pharma | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
CN113372276B (zh) * | 2021-05-25 | 2022-04-22 | 三峡大学 | 吲唑类衍生物及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1974379A (en) * | 1932-10-12 | 1934-09-18 | Cinch Mfg Corp | Coupling device for hose and like connections |
US1966325A (en) * | 1933-06-28 | 1934-07-10 | Verne E Welch | Pump |
GB865341A (en) * | 1958-07-30 | 1961-04-12 | Bayer Ag | 5-benzene-sulphonamido-1-phenyl pyrazole derivatives |
GB926327A (en) | 1960-05-13 | 1963-05-15 | Ici Ltd | New dyestuffs of the azostilbene series containing halopyrimidyl residues |
NL6707299A (pt) * | 1966-07-16 | 1968-01-17 | ||
GB1145544A (en) | 1966-07-16 | 1969-03-19 | Polichimica Sap S P A | New tetrahydroindazoles |
CZ20024151A3 (cs) | 2000-06-23 | 2003-05-14 | Takeda Chemical Industries, Ltd. | Benzoxazepinony, způsob jejich výroby a použití |
US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
CN100448869C (zh) * | 2002-11-27 | 2009-01-07 | 拜尔药品公司 | 用于治疗糖尿病的苯胺基吡唑衍生物 |
AR042067A1 (es) * | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
EP1698335A4 (en) * | 2003-12-26 | 2007-08-01 | Ono Pharmaceutical Co | AGENT FOR PREVENTING AND / OR TREATING DISEASES INVOLVING A MITOCHONDRIAL BENZODIAZEPINE RECEPTOR |
CN101304975A (zh) | 2005-11-09 | 2008-11-12 | 艾博特公司 | P2x7受体拮抗剂及其用途 |
CA2631746A1 (en) | 2005-12-01 | 2007-06-07 | Bayer Healthcare Llc | Urea compounds useful in the treatment of cancer |
-
2009
- 2009-09-15 CN CN200980137912.0A patent/CN102164900B/zh not_active Expired - Fee Related
- 2009-09-15 ES ES09783046.7T patent/ES2443947T3/es active Active
- 2009-09-15 KR KR1020117009165A patent/KR101444988B1/ko not_active IP Right Cessation
- 2009-09-15 AU AU2009295967A patent/AU2009295967A1/en not_active Abandoned
- 2009-09-15 WO PCT/EP2009/061966 patent/WO2010034657A1/en active Application Filing
- 2009-09-15 CA CA2736434A patent/CA2736434A1/en not_active Abandoned
- 2009-09-15 BR BRPI0919248A patent/BRPI0919248A2/pt not_active IP Right Cessation
- 2009-09-15 JP JP2011528291A patent/JP5450632B2/ja not_active Expired - Fee Related
- 2009-09-15 MX MX2011002793A patent/MX2011002793A/es active IP Right Grant
- 2009-09-15 EP EP09783046.7A patent/EP2346834B1/en not_active Not-in-force
- 2009-09-21 US US12/563,189 patent/US8153663B2/en not_active Expired - Fee Related
- 2009-09-22 TW TW098131981A patent/TW201020234A/zh unknown
- 2009-09-23 AR ARP090103663A patent/AR073396A1/es unknown
-
2011
- 2011-03-10 IL IL211674A patent/IL211674A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ES2443947T3 (es) | 2014-02-21 |
TW201020234A (en) | 2010-06-01 |
US8153663B2 (en) | 2012-04-10 |
MX2011002793A (es) | 2011-04-05 |
US20100076026A1 (en) | 2010-03-25 |
AR073396A1 (es) | 2010-11-03 |
KR101444988B1 (ko) | 2014-09-26 |
AU2009295967A1 (en) | 2010-04-01 |
JP2012503618A (ja) | 2012-02-09 |
JP5450632B2 (ja) | 2014-03-26 |
CN102164900A (zh) | 2011-08-24 |
WO2010034657A1 (en) | 2010-04-01 |
EP2346834A1 (en) | 2011-07-27 |
EP2346834B1 (en) | 2013-11-20 |
CN102164900B (zh) | 2014-04-16 |
IL211674A0 (en) | 2011-06-30 |
KR20110059890A (ko) | 2011-06-07 |
CA2736434A1 (en) | 2010-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0919248A2 (pt) | derivados de 3-amino-indazol ou 3-amino-4,5,6,7-tetraidroindazol | |
BRPI0811718A2 (pt) | Derivados de 3,3-espiroindolinona | |
ATE555107T1 (de) | 2-aza-bicyclo-ä2,2,1-üheptan-derivate | |
BRPI0907563A2 (pt) | Derivados de 4,5-di-hidro-xazol-2-il amina | |
BRPI0816970A2 (pt) | 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas | |
ATE469145T1 (de) | 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl- | |
BRPI0923730A2 (pt) | "elemento deslizante". | |
BRPI0906607A2 (pt) | Agentes de coalescência eficazes. | |
ATE481383T1 (de) | 3-aza-bicycloä3.1.0ühexanderivate | |
ATE540040T1 (de) | Dioxabicycloä3.2.1üoctan-2,3,4-triolderivate | |
DE602008005634D1 (de) | 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate | |
BRPI0918472A2 (pt) | composto 2,4-diaminopirimidina | |
BRPI0910229A2 (pt) | Tetramatos de 4';4'-dioxaspiro espirociclicamente substituídos | |
BRPI0813235A2 (pt) | Combinação anti-helmíntica. | |
BRPI0923047A2 (pt) | "conjugados de proteínas-oligossacarídeos". | |
BRPI0814745A2 (pt) | Composição de produto. | |
BRPI0923048A2 (pt) | "composto de aminopirazol". | |
DE602007001681D1 (de) | 1,3-dioxan-carboxylsäuren | |
BRPI0916363A2 (pt) | derivados de 4,5-di-hidro-oxazol-2-ila | |
BRPI0917446A2 (pt) | derivados de acilaminobenzamida. | |
BRPI0716046A2 (pt) | composiÇÕes de nanopartÍcula. | |
BRPI0815059A2 (pt) | Derivado de 1,3-di-hidroisoindol | |
BRPI0906714A2 (pt) | Derivados de oxazepinopirimidona heteroarilamida substituídos. | |
FR2928371B1 (fr) | Derive de cysteine. | |
BRPI0816679A2 (pt) | Derivados de ftalazinona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |